Clinical Design and Patient Selection

The RxFINE-Low trial, conducted by the National Cancer Institute (NCI) and the ECOG-ACRIN Cancer Research Group, is a randomized, active-controlled phase 3 study. It includes post-surgical patients with high-risk, hormone receptor (HR)-positive, HER2-negative breast cancer and an Oncotype DX recurrence score (RS) of 0-25. Participants include postmenopausal women and men. The trial compares a standard chemotherapy regimen followed by endocrine therapy plus Kisqali to endocrine therapy plus Kisqali alone, without prior chemotherapy. By isolating a population with high anatomical risk but low genomic risk, the study aims to validate the incremental benefit of chemotherapy.

Drugs and Evaluation Criteria

Kisqali (ribociclib) is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor from Novartis AG (NVS) that inhibits RB protein phosphorylation and the G1-S cell cycle progression of cancer cells. Both arms will administer ribociclib for up to 3 years, along with endocrine therapy based on an aromatase inhibitor (letrozole, anastrozole, or exemestane) for at least 5 years. The primary endpoint is non-inferiority in invasive breast cancer-free survival (iBCFS), with secondary endpoints including 5-year invasive disease-free survival, distant recurrence, overall survival, and short- and long-term toxicity. Therefore, this study examines whether chemotherapy can be omitted in the context of CDK4/6 inhibitors, which are already commonly administered, rather than evaluating the efficacy of ribociclib itself.

Regulatory and Competitive Landscape

The U.S. FDA approved Kisqali in combination with an aromatase inhibitor for adjuvant treatment of high-risk, HR-positive, HER2-negative early breast cancer on September 17, 2024. The European Commission also approved the same indication for early breast cancer on November 27, 2024, based on the NATALEE phase 3 trial involving 5,101 patients. The direct competitor is Verzenio (abemaciclib) from Eli Lilly and Company (LLY), another CDK4/6 inhibitor, which received FDA approval on March 3, 2023, for adjuvant treatment of high-risk, early breast cancer with positive lymph nodes. However, the actual comparator in RxFINE-Low is not Verzenio but chemotherapy; therefore, success will shift the focus of competition from market share among drugs to patient selection and reduced treatment intensity.

Market and Business Implications

The HR-positive, HER2-negative breast cancer treatment market is projected to expand from USD 14.47 billion in 2025 to USD 30.42 billion in 2034, and Kisqali's net sales in 2025 were USD 4.783 billion, a 58% increase year-over-year. This reflects both an increase in the share of metastatic breast cancer and an expansion of prescriptions for early breast cancer. If non-inferiority is achieved, it will strengthen the clinical role of Kisqali-based long-term adjuvant therapy by reducing chemotherapy-related toxicity, treatment costs, and treatment duration in patients with high-stage disease and a recurrence score of 0-25. Conversely, if the non-inferiority criterion is not met, it will establish evidence that it is difficult to exclude chemotherapy in patients with high anatomical risk based solely on low genomic risk.